{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T15:20:31Z","timestamp":1788967231365,"version":"build-2803163510"},"reference-count":64,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T00:00:00Z","timestamp":1724889600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"NHMRC Emerging Leader 2 Fellowship"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,5,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The World Health Organization has recommended that the management of chronic diseases such as inflammatory bowel disease (IBD) should be undertaken using an integrated approach delivered by a multidisciplinary team. Although the composition of an IBD multidisciplinary team has been well described, the inclusion of an IBD pharmacist as a core member has been more recent, with variable uptake within IBD services internationally. While pharmacists continue to play the traditional role of safe prescribing and monitoring of immunosuppressive therapies, their role within the IBD team is rapidly expanding; however, the value, in terms of both clinical outcomes as well as financial savings (where available), which they add to IBD services has been less well described. In this narrative review, we perform a comprehensive evaluation of the literature detailing the expanding roles that IBD pharmacists play and describe opportunities that exist for integrated pharmacists to add value to IBD service delivery. Medication and adherence counseling, immunosuppressive monitoring, uptake of biosimilars, therapeutic drug monitoring, health promotion and prevention appear to be key areas where integrated pharmacists can add the most value to IBD patients and services. In particular, integrated IBD pharmacists can improve patient outcomes via rigorous monitoring pre and post initiation of drug therapies; focused medication counseling; advice on improving adherence; implementation of novel approaches to medication usage, and; strategies to help sustain IBD service delivery. These data can be used to further build a case for those seeking to add pharmacists to their team\/services. Future studies should focus on evaluating the impact of an integrated IBD pharmacist on quality-of-care delivery together with the clinical and financial value added to IBD services compared to services that lack an integrated IBD pharmacist role.<\/jats:p>","DOI":"10.1093\/ibd\/izae196","type":"journal-article","created":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T15:21:14Z","timestamp":1724944874000},"page":"1419-1429","source":"Crossref","is-referenced-by-count":8,"title":["How Does an Integrated Pharmacist Add Value in the Management of Inflammatory Bowel Disease in the Era of Values-Based Healthcare?"],"prefix":"10.1093","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8749-0855","authenticated-orcid":false,"given":"Patrick","family":"Hilley","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, The Austin Hospital , Melbourne ,","place":["Australia"]},{"name":"Department of Medicine, Austin Academic Centre, University of Melbourne , Melbourne ,","place":["Australia"]},{"name":"Department of Pharmacy, The Austin Hospital , Melbourne ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1490-0547","authenticated-orcid":false,"given":"Darren","family":"Wong","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, The Austin Hospital , Melbourne ,","place":["Australia"]},{"name":"Department of Medicine, Austin Academic Centre, University of Melbourne , Melbourne ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3399-7236","authenticated-orcid":false,"given":"Peter","family":"De Cruz","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, The Austin Hospital , Melbourne ,","place":["Australia"]},{"name":"Department of Medicine, Austin Academic Centre, University of Melbourne , Melbourne ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,8,29]]},"reference":[{"issue":"1","key":"2025051303562421900_CIT0001","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/s41575-020-00360-x","article-title":"The four epidemiological stages in the global evolution of inflammatory bowel disease","volume":"18","author":"Kaplan","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol."},{"issue":"5","key":"2025051303562421900_CIT0002","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1053\/j.gastro.2020.12.031","article-title":"STRIDE-II: an update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD","volume":"160","author":"Turner","year":"2021","journal-title":"Gastroenterology."},{"issue":"1","key":"2025051303562421900_CIT0003","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1093\/jcag\/gwy060","article-title":"Integrated care models: optimizing adult ambulatory care in inflammatory bowel disease","volume":"3","author":"Schoenfeld","year":"2020","journal-title":"J Can Assoc Gastroenterol."},{"issue":"3","key":"2025051303562421900_CIT0004","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1093\/ibd\/izy276","article-title":"Quality of care in patients with inflammatory bowel disease","volume":"25","author":"Jackson","year":"2018","journal-title":"Inflamm Bowel Dis."},{"issue":"5","key":"2025051303562421900_CIT0005","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/S2468-1253(23)00003-1","article-title":"The cost of inflammatory bowel disease in high-income settings: a Lancet Gastroenterology & Hepatology Commission","volume":"8","author":"Burisch","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"Suppl. 3","key":"2025051303562421900_CIT0006","doi-asserted-by":"publisher","first-page":"s1","DOI":"10.1136\/gutjnl-2019-318484","article-title":"British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults","volume":"68","author":"Lamb","year":"2019","journal-title":"Gut."},{"issue":"1","key":"2025051303562421900_CIT0007","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1136\/flgastro-2017-100835","article-title":"Establishing the aims, format and function for multidisciplinary team-driven care within an Inflammatory Bowel Disease service: a multicentre qualitative specialist-based consensus study","volume":"9","author":"Morar","year":"2018","journal-title":"Frontline Gastroenterol"},{"issue":"7","key":"2025051303562421900_CIT0008","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1111\/imj.14187","article-title":"Crohn\u2019s & Colitis Australia inflammatory bowel disease audit: measuring the quality of care in Australia","volume":"49","author":"Massuger","year":"2019","journal-title":"Intern Med J."},{"issue":"6","key":"2025051303562421900_CIT0009","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1093\/ibd\/izad143","article-title":"Defining the roles of inflammatory bowel disease clinical pharmacists in the united states: a systematic review and National RAND\/UCLA Consensus","volume":"30","author":"Bhat","year":"2023","journal-title":"Inflamm Bowel Dis."},{"issue":"12","key":"2025051303562421900_CIT0010","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1111\/apt.15742","article-title":"A virtual clinic increases anti-TNF dose intensification success via a treat-to-target approach compared with standard outpatient care in Crohn\u2019s disease","volume":"51","author":"Srinivasan","year":"2020","journal-title":"Aliment Pharmacol Ther."},{"issue":"1","key":"2025051303562421900_CIT0011","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s13643-021-01626-4","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"10","author":"Page","year":"2021","journal-title":"Syst Rev"},{"issue":"5","key":"2025051303562421900_CIT0012","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1111\/imj.15822","article-title":"Impact of a pharmacist-led thiopurine monitoring service in outpatients with inflammatory bowel disease","volume":"53","author":"Rodda","year":"2023","journal-title":"Intern Med J."},{"issue":"3","key":"2025051303562421900_CIT0013","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1111\/jgh.13158","article-title":"The role of a pharmacist in the inflammatory bowel disease clinic","volume":"30","author":"Rentsch","year":"2015","journal-title":"J Gastroenterol Hepatol."},{"issue":"6","key":"2025051303562421900_CIT0014","doi-asserted-by":"publisher","first-page":"S","DOI":"10.1016\/s0016-5085(18)32756-2","article-title":"Does a pharmacist working in an out-patient clinic improve safety for patients with inflammatory bowel diease","volume":"154","author":"Morgan","year":"2018","journal-title":"Gastroenterology."},{"issue":"Suppl 1","key":"2025051303562421900_CIT0015","doi-asserted-by":"publisher","first-page":"A137","DOI":"10.1136\/ejhpharm-2019-eahpconf.296","article-title":"Clinical experience of optimising co-administration therapy of low-dose allopurinol with low-dose thiopurines in inflammatory bowel disease patients attending a virtual pharmacist clinic","volume":"26","author":"Fuertes","year":"2019","journal-title":"Eur J Hosp Pharm."},{"issue":"Suppl 1","key":"2025051303562421900_CIT0016","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1136\/gutjnl-2014-307263.489","article-title":"Our experience of a pharmacist led immunomodulator (IMD) clinic: a novel service in a district general hospital","volume":"63","author":"Sathyanarayana","year":"2014","journal-title":"Gut."},{"issue":"Suppl 8","key":"2025051303562421900_CIT0017","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1177\/205064061985467","article-title":"Specialist pharmacist led immunomodulator service review\u20141 year outcome in a UK District Hospital","volume":"7","author":"Richards","year":"2019","journal-title":"United Eur Gastroenterol J"},{"issue":"Supplement_2","key":"2025051303562421900_CIT0018","doi-asserted-by":"publisher","first-page":"S55","DOI":"10.1093\/ajhp\/zxac354","article-title":"Development and implementation of a laboratory monitoring dashboard to reduce treatment gaps in inflammatory bowel disease","volume":"80","author":"Kozlicki","year":"2022","journal-title":"Am J Health Syst Pharm."},{"issue":"Suppl 2","key":"2025051303562421900_CIT0019","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1080\/03007995.2022.2108606","article-title":"Pharmacist driven appeals process in an IBD clinic","volume":"39","author":"Stewart","year":"2023","journal-title":"Curr Med Res Opin."},{"issue":"sup2","key":"2025051303562421900_CIT0020","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1080\/03007995.2023.2236891","article-title":"The impact of a multi-step order transmittal in inflammatory bowel disease clinic","volume":"39","author":"Hammond","year":"2023","journal-title":"Curr Med Res Opin."},{"issue":"2","key":"2025051303562421900_CIT0021","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/crocol\/otad018","article-title":"Role and impact of a clinical pharmacy team at an Inflammatory Bowel Disease Center","volume":"5","author":"Choi","year":"2023","journal-title":"Crohn\u2019s Colitis."},{"issue":"4","key":"2025051303562421900_CIT0022","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1053\/j.gastro.2015.06.002","article-title":"Identification of patients with variants in TPMT and dose reduction reduces hematologic events during thiopurine treatment of inflammatory bowel disease","volume":"149","author":"Coenen","year":"2015","journal-title":"Gastroenterology."},{"issue":"8","key":"2025051303562421900_CIT0023","doi-asserted-by":"publisher","first-page":"767","DOI":"10.2165\/00019053-200624080-00004","article-title":"Pharmacoeconomic analyses of azathioprine, methotrexate and prospective pharmacogenetic testing for the management of inflammatory bowel disease","volume":"24","author":"Priest","year":"2006","journal-title":"PharmacoEcon."},{"issue":"Suppl 3","key":"2025051303562421900_CIT0024","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1111\/jgh.14435","article-title":"Swiss cheese tragedy case study","volume":"33","author":"Thin","year":"2018","journal-title":"J Gastroenterol Hepatol."},{"issue":"2","key":"2025051303562421900_CIT0025","doi-asserted-by":"publisher","first-page":"228","DOI":"10.5005\/jp-journals-10071-23738","article-title":"Thiopurine-induced myelosuppression with severe sepsis in a patient with Crohn\u2019s disease: a case report","volume":"25","author":"Debnath","year":"2021","journal-title":"Indian J Crit Care Med"},{"issue":"23","key":"2025051303562421900_CIT0026","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.12659\/AJCR.914166","article-title":"Pancytopenia and septic infection caused by concurrent use of allopurinol and mercaptopurine: a case report illustrating the importance of clinical pharmacist consultation","volume":"20","author":"Alhubaishi","year":"2019","journal-title":"Am J Case Rep"},{"issue":"8","key":"2025051303562421900_CIT0027","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1002\/ueg2.12290","article-title":"A pharmacist-led post induction review clinic improves compliance with key performance indicators for patients newly started on biologic therapies in inflammatory bowel disease","volume":"10","author":"Al-Zarrad","year":"2022","journal-title":"United European Gastroenterol J"},{"issue":"3","key":"2025051303562421900_CIT0028","doi-asserted-by":"publisher","first-page":"S87","DOI":"10.1053\/j.gastro.2019.11.218","article-title":"P001 pharmacist role in IBD medication optimization (Primo-IBD)","volume":"158","author":"Kim","year":"2020","journal-title":"Gastroenterology."},{"issue":"11","key":"2025051303562421900_CIT0029","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1248\/yakushi.23-00006","article-title":"Usefulness of pharmacist outpatient services for inflammatory bowel disease","volume":"143","author":"Hirata","year":"2023","journal-title":"Yakugaku Zasshi."},{"issue":"7941","key":"2025051303562421900_CIT0030","doi-asserted-by":"publisher","DOI":"10.1211\/PJ.2020.20208317","article-title":"Evaluation of a pharmacist-led virtual thiopurine clinic","volume":"305","author":"Fuertes","year":"2020","journal-title":"Pharmaceut J"},{"issue":"4","key":"2025051303562421900_CIT0031","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1111\/apt.17042","article-title":"Inflammatory bowel disease patient-reported quality assessment should drive service improvement: a national survey of UK IBD units and patients","volume":"56","author":"Hawthorne","year":"2022","journal-title":"Aliment Pharmacol Ther."},{"issue":"5","key":"2025051303562421900_CIT0032","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/s0016-5085(11)60836-6","article-title":"A structured program of pharmaceutical care benefits outpatients with inflammatory bowel diseases undergoing continuous drug therapy","volume":"140","author":"Dewulf","year":"2011","journal-title":"Gastroenterology."},{"issue":"5","key":"2025051303562421900_CIT0033","doi-asserted-by":"publisher","first-page":"736","DOI":"10.5009\/gnl210371","article-title":"Improvement in medication adherence after pharmacist intervention is associated with favorable clinical outcomes in patients with ulcerative colitis","volume":"16","author":"Kim","year":"2022","journal-title":"Gut Liver"},{"issue":"5","key":"2025051303562421900_CIT0034","first-page":"215","article-title":"The pharmacist\u2019s role in biologic management for IBD in a health system\u2013integrated practice model","volume":"7","author":"Bhat","year":"2015","journal-title":"Am J Pharm Benefits"},{"key":"2025051303562421900_CIT0035","article-title":"Estimating patient adherence to medication with electronic health records data and pharmacy claims combined","volume":"167","author":"Zhao","year":"2013","journal-title":"Pharma Health Care."},{"issue":"3","key":"2025051303562421900_CIT0036","doi-asserted-by":"publisher","first-page":"381","DOI":"10.5530\/jyp.2017.9.76","article-title":"Clinical Pharmacist\u2019s interventions on medication adherence and knowledge of inflammatory bowel disease patients","volume":"9","author":"Ashok","year":"2017","journal-title":"J Young Pharm."},{"issue":"8","key":"2025051303562421900_CIT0037","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1097\/MIB.0000000000001194","article-title":"Inflammatory bowel disease pharmacist adherence counseling improves medication adherence in Crohn\u2019s disease and ulcerative colitis","volume":"23","author":"Tiao","year":"2017","journal-title":"Inflamm Bowel Dis."},{"issue":"7","key":"2025051303562421900_CIT0038","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1097\/MIB.0000000000001114","article-title":"Pediatric-to-adult transition and medication adherence in patients with inflammatory bowel disease","volume":"23","author":"Jeganathan","year":"2017","journal-title":"Inflamm Bowel Dis."},{"issue":"2","key":"2025051303562421900_CIT0039","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1038\/ajg.2016.537","article-title":"ACG clinical guideline: preventive care in inflammatory bowel disease","volume":"112","author":"Farraye","year":"2017","journal-title":"Am J Gastroenterol | ACG"},{"issue":"9","key":"2025051303562421900_CIT0040","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1097\/MCG.0000000000001635","article-title":"The burden of vaccine-preventable diseases in patients with inflammatory bowel disease","volume":"56","author":"Kr\u00f6ner","year":"2022","journal-title":"J Clin Gastroenterol."},{"issue":"8","key":"2025051303562421900_CIT0041","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1007\/s10620-016-4146-x","article-title":"Preventative care in the patient with inflammatory bowel disease: what is new","volume":"61","author":"Reich","year":"2016","journal-title":"Dig Dis Sci."},{"issue":"5","key":"2025051303562421900_CIT0042","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1016\/j.japh.2022.06.008","article-title":"The impact of pharmacist involvement on immunization uptake and other outcomes: an updated systematic review and meta-analysis","volume":"62","author":"Le","year":"2022","journal-title":"J Am Pharm Assoc (2003)."},{"issue":"1","key":"2025051303562421900_CIT0043","doi-asserted-by":"publisher","first-page":"e29","DOI":"10.1053\/j.gastro.2021.05.022","article-title":"The Role of a pharmacist in improving vaccination discussions and completion in patients with inflammatory bowel disease","volume":"161","author":"Nasser-Ghodsi","year":"2021","journal-title":"Gastroenterology."},{"issue":"12","key":"2025051303562421900_CIT0044","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1002\/jac5.1732","article-title":"Using clinical pharmacists to close the herpes zoster vaccination gap in IBD patients in a county medical center","volume":"5","author":"Quyen","year":"2022","journal-title":"JACCP"},{"issue":"6","key":"2025051303562421900_CIT0045","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1177\/08971900211000682","article-title":"Improved smoking cessation rates in a pharmacist-led program embedded in an inflammatory bowel disease specialty medical home","volume":"35","author":"Tse","year":"2022","journal-title":"J Pharm Pract"},{"issue":"3","key":"2025051303562421900_CIT0046","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.crohns.2012.04.011","article-title":"High smoking cessation rate in Crohn\u2019s disease patients after physician advice\u2014The TABACROHN Study","volume":"7","author":"Nunes","year":"2013","journal-title":"J Crohns Colitis."},{"key":"2025051303562421900_CIT0047","doi-asserted-by":"publisher","first-page":"S319","DOI":"10.14309\/01.ajg.0000776340.56908.1c","article-title":"S702 evaluation of a novel pharmacy program for reducing variation in prescribing biologics for inflammatory bowel disease","volume":"116","author":"Chan","year":"2021","journal-title":"Am J Gastroenterol | ACG"},{"issue":"4","key":"2025051303562421900_CIT0048","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1093\/ibd\/izab110","article-title":"Increasing biosimilar utilization at a pediatric inflammatory bowel disease center and associated cost savings: show me the money","volume":"28","author":"Morris","year":"2021","journal-title":"Inflamm Bowel Dis."},{"issue":"suppl_1","key":"2025051303562421900_CIT0049","doi-asserted-by":"publisher","first-page":"S348","DOI":"10.1093\/ecco-jcc\/jjx002.651","article-title":"P527 Infliximab biosimilar switching program overseen by specialist pharmacist saves money, realises investment and optimises therapy","volume":"11","author":"St. Clair Jones","year":"2017","journal-title":"J Crohns Colitis"},{"issue":"Supplement 1","key":"2025051303562421900_CIT0050","doi-asserted-by":"publisher","first-page":"P428","DOI":"10.1093\/ecco-jcc\/jjac190.0558","article-title":"Pharmacist led clinic in inflammatory bowel disease","volume":"17","author":"Kwok","year":"2017","journal-title":"J Crohns Colitis."},{"issue":"Supplement 1","key":"2025051303562421900_CIT0051","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1136\/ejhpharm-2019-eahpconf.293","article-title":"Establishment of a pharmaceutical standardised interview concerning biosimilars of infliximab in the daycare clinic of a Gastroenterology Department for patients affected by inflammatory bowel disease","volume":"26","author":"Coget","year":"2019","journal-title":"Eur J Hosp Pharm."},{"issue":"2","key":"2025051303562421900_CIT0052","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.dld.2019.11.004","article-title":"Multidisciplinary management of the Nocebo effect in biosimilar-treated IBD patients: results of a workshop from the NOCE-BIO consensus group","volume":"52","author":"D\u2019Amico","year":"2020","journal-title":"Dig Liver Dis."},{"issue":"2","key":"2025051303562421900_CIT0053","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1111\/ijpp.12485","article-title":"Differences in UK healthcare professionals\u2019 knowledge, attitude and practice towards infliximab and insulin glargine biosimilars","volume":"27","author":"Aladul","year":"2018","journal-title":"Int J Pharm Pract."},{"issue":"3","key":"2025051303562421900_CIT0054","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1097\/FTD.0000000000001044","article-title":"Pharmacist-driven therapeutic infliximab monitoring at the point of care using rapidly assessed drug levels in patients with inflammatory bowel disease","volume":"45","author":"Rentsch","year":"2023","journal-title":"Ther Drug Monit."},{"issue":"Supplement 1","key":"2025051303562421900_CIT0055","doi-asserted-by":"publisher","first-page":"A142","DOI":"10.1136\/ejhpharm-2019-eahpconf.306","article-title":"4CPS-157 tumour necrosis factor inhibitors: utility of pharmacokinetics monitoring in inflammatory bowel disease management","volume":"26","author":"Llinares","year":"2019","journal-title":"Eur J Hosp Pharm"},{"issue":"Supplement 1","key":"2025051303562421900_CIT0056","doi-asserted-by":"publisher","first-page":"A1","DOI":"10.1136\/ejhpharm-2019-eahpconf.307","article-title":"4CPS-158 clinical benefit of infliximab monitoring in inflammatory bowel disease","volume":"26","author":"Llinares","year":"2019","journal-title":"Eur J Hosp Pharm."},{"issue":"6","key":"2025051303562421900_CIT0057","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1111\/imj.16311","article-title":"Transitioning patients from intravenous to subcutaneous infliximab and vedolizumab for inflammatory bowel disease: what is the opportunity cost of improving access to healthcare","volume":"54","author":"Hilley","year":"2024","journal-title":"Intern Med J."},{"issue":"6","key":"2025051303562421900_CIT0058","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1093\/ecco-jcc\/jjw216","article-title":"Biosimilar infliximab in inflammatory bowel disease: outcomes of a managed switching programme","volume":"11","author":"Razanskaite","year":"2017","journal-title":"J Crohns Colitis."},{"issue":"Supplement_1","key":"2025051303562421900_CIT0059","doi-asserted-by":"publisher","first-page":"i556","DOI":"10.1093\/ecco-jcc\/jjac190.0558","article-title":"P428 Pharmacist led clinic in inflammatory bowel disease","volume":"17","author":"Kwok","year":"2023","journal-title":"J Crohns Colitis."},{"issue":"6","key":"2025051303562421900_CIT0060","doi-asserted-by":"publisher","first-page":"S-633","DOI":"10.1016\/S0016-5085(19)38484-7","article-title":"1847 \u2013 rapid 30-Minute Infliximab infusion protocols are safe and effective when switching inflammatory bowel disease (IBD) patients from originator to biosimilar infliximab","volume":"156","author":"Srinivasan","year":"2019","journal-title":"Gastroenterology."},{"issue":"7948","key":"2025051303562421900_CIT0061","doi-asserted-by":"publisher","DOI":"10.1211\/PJ.2021.1.81070","article-title":"Only 13% of IBD teams meet standards for pharmacist involvement","volume":"306","author":"Burns","year":"2021","journal-title":"Pharm J"},{"issue":"Supplement_1","key":"2025051303562421900_CIT0062","doi-asserted-by":"publisher","first-page":"S535","DOI":"10.1093\/ecco-jcc\/jjab076.701","article-title":"IBDUK. P580 benchmarking IBD pharmacy services to optimise, strengthen and align IBD expert pharmacy practice","volume":"15","author":"St Clair Jones","year":"2021","journal-title":"J Crohns Colitis."},{"issue":"1","key":"2025051303562421900_CIT0063","doi-asserted-by":"publisher","first-page":"otab084","DOI":"10.1093\/crocol\/otab084","article-title":"Healthcare needs and perceptions of people living with inflammatory bowel disease in Australia: a mixed-methods study","volume":"4","author":"Prasad","year":"2022","journal-title":"Crohn\u2019s & Colitis 360"},{"issue":"10","key":"2025051303562421900_CIT0064","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.3390\/healthcare10101818","article-title":"The role of clinical pharmacists in improving quality of care in patients with inflammatory bowel disease: an evaluation of patients\u2019 and physicians\u2019 satisfaction","volume":"10","author":"Alrashed","year":"2022","journal-title":"Healthcare (Basel)"}],"container-title":["Inflammatory Bowel Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ibdjournal\/advance-article-pdf\/doi\/10.1093\/ibd\/izae196\/58963790\/izae196.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/31\/5\/1419\/58963790\/izae196.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/31\/5\/1419\/58963790\/izae196.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T07:56:27Z","timestamp":1747122987000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article\/31\/5\/1419\/7745062"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,29]]},"references-count":64,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,8,29]]},"published-print":{"date-parts":[[2025,5,12]]}},"URL":"https:\/\/doi.org\/10.1093\/ibd\/izae196","relation":{},"ISSN":["1078-0998","1536-4844"],"issn-type":[{"value":"1078-0998","type":"print"},{"value":"1536-4844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,5]]},"published":{"date-parts":[[2024,8,29]]}}}